Grant: Operating Grant: Secondary Data Analysis for Cancer Prevention and Control
University of Ottawa
$75,000.00
Impact of genome-wide and local homozygosity on cancer
FY 2017-18
Summary
It is well known that homozygosity, when an individual has two identical forms of a particular gene, one inherited from each parent, causes rare, often very severe, Mendelian genetic diseases. However, the health impact of increased homozygosity on diseases caused by many genes and the environment is not well understood. Most human populations display restricted ranges of homozygosity levels. Hence, in these populations, very large numbers of individuals are needed to investigate the health impact of homozygosity. Populations that originate from a limited number of individuals and remain isolated to some extent from other populations are called founder populations. Large founder populations such as Quebec allow the measurement of a wide range of homozygosity levels and are thus ideal to efficiently study homozygosity and its impact on health. The overall goal of our proposed research is to take advantage of the Quebec founder population to study the impact of homozygosity on cancer by combining a smaller sample from Quebec to larger samples from non-founder populations. We will focus on prostate cancer. Animal studies have shown that non-additive genetic variation (underlying homozygosity effects) plays an important role in genetic disease risk but is less often studies than additive genetic variation. Our research will thus provide much needed insights on non-additive effects for cancer and could ultimately result in better health management of these traits.
Department
Program
Operating Grant: Secondary Data Analysis for Cancer Prevention and Control
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
377917
Name
Roy-Gagnon Marie-Hélène
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Genetics
Theme2
Biomedical
Prcname2
Secondary Data Analysis - All Other Cancers
Projecttitle
Impact of genome-wide and local homozygosity on cancer
Programtype2
Operating Grants
Orgnameinp2
University of Ottawa
Cihramount2
$75,000
Cihrequipment2
$0
Programname2
Operating Grant: Secondary Data Analysis for Cancer Prevention and Control
Keyworddelim
Founder Population; Honmozygosity By Descent; Population Genetics; Prostate Cancer; Statistical Genetics
Abstract
It is well known that homozygosity, when an individual has two identical forms of a particular gene, one inherited from each parent, causes rare, often very severe, Mendelian genetic diseases. However, the health impact of increased homozygosity on diseases caused by many genes and the environment is not well understood. Most human populations display restricted ranges of homozygosity levels. Hence, in these populations, very large numbers of individuals are needed to investigate the health impact of homozygosity. Populations that originate from a limited number of individuals and remain isolated to some extent from other populations are called founder populations. Large founder populations such as Quebec allow the measurement of a wide range of homozygosity levels and are thus ideal to efficiently study homozygosity and its impact on health. The overall goal of our proposed research is to take advantage of the Quebec founder population to study the impact of homozygosity on cancer by combining a smaller sample from Quebec to larger samples from non-founder populations. We will focus on prostate cancer. Animal studies have shown that non-additive genetic variation (underlying homozygosity effects) plays an important role in genetic disease risk but is less often studies than additive genetic variation. Our research will thus provide much needed insights on non-additive effects for cancer and could ultimately result in better health management of these traits.
Competitiondate
201711
Approvedterm2
1 yr 0 mth
Pinamesdelim
Roy-Gagnon, Marie-Hélène; Burkett, Kelly M
Approvedterm
1 an 0 mois
Cihrcontribution2
Inst of Cancer Research~ $75,000~ $0~